Perrigo Launches Generic Axiron Topical Solution

The solution is indicated as a replacement therapy for conditions of deficiency or absence of endogenous testosterone
The solution is indicated as a replacement therapy for conditions of deficiency or absence of endogenous testosterone

Perrigo announced the launch of its Testosterone Topical Solution 30mg/1.5mL, the generic version of Eli Lilly's Axiron Topical Solution. The Food and Drug Administration (FDA) initially approved Perrigo's version in March 2017.

Axiron Topical Solution is indicated as replacement therapy in males for conditions associated with deficiency or absence of endogenous testosterone, such as primary hypogonadism or hypogonadotropic hypogonadism (congenital or acquired). Endogenous androgens, including testosterone and dihydrotestosterone (DHT), are responsible for the normal growth and development of male sex organs and for the maintenance of secondary sex characteristics. Testosterone and DHT are necessary for normal development of secondary sex characteristics.  

Related Articles

 

Testosterone Topical Solution, a CIII controlled substance, is available as 30mg/1.5mL strength. 

For more information call (866) 634-9120 or visit Perrigo.com